A
Ascendis Pharma A/S (ASND)
NMS – Real vaqt narxi. Valyuta: USD
260.75
-0.83 (-0.32%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
261.00
+0.25 (0.10%)
Bozordan keyin: Jun 26, 2026, 4:48 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
260.75
-0.83 (-0.32%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
261.00
+0.25 (0.10%)
Bozordan keyin: Jun 26, 2026, 4:48 PM EDT
Ascendis Pharma A/S Yevropa, Qo'shma Shtatlar va xalqaro miqyosda tibbiy ehtiyojlarni qondirish uchun TransCon asosidagi terapiyalarni ishlab chiqishga qaratilgan biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniya o'sish gormoni etishmovchiligi bo'lgan bolalarni davolash uchun SKYTROFA; va surunkali gipoparatiroidizm bilan og'rigan kattalarni davolash uchun kuniga bir marta ter underiga yuboriladigan YORVIPATHni taklif etadi. Shuningdek, u klinik rivojlanish bosqichidagi uchta mustaqil endokrinologiya noyob kasalliklari mahsulot nomzodlarining portfelini ishlab chiqmoqda, shuningdek, onkologiya terapevtik nomzodlarini ilgari surishga qaratilgan. Kompaniya 2006 yilda tashkil etilgan va Daniyaning Hellerup shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
| Mr. Chad Fugure | Vice President of Investor Relations |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-17 | 6-K | d78361d6k.htm |
| 2026-06-15 | 6-K | d48156d6k.htm |
| 2026-06-12 | 6-K | d136465d6k.htm |
| 2026-06-10 | 6-K | d85296d6k.htm |
| 2026-05-22 | SD | d227592dsd.htm |
| 2026-05-13 | 6-K | d865415d6k.htm |
| 2026-05-07 | 6-K | asnd-20260331.htm |
| 2026-04-21 | 6-K | d91071d6k.htm |
| 2026-04-20 | 8-A12B/A | d51268d8a12ba.htm |
| 2026-04-20 | 6-K | d620541d6k.htm |